Latest Ratios: P/E Ratio 79.8x · EV/EBITDA 10.5x · ROE 0.8%. (2018–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $722M | $770M | $935M | $664M | $3.1B | $4.9B | $5.5B | — | — |
| Enterprise Value | $3.3B | $3.4B | $3.7B | $3.6B | $6.1B | $7.7B | $8.4B | — | — |
| P/E Ratio → | 79.81 | 84.86 | — | — | 34.53 | 29.52 | — | — | — |
| P/S Ratio | 0.12 | 0.13 | 0.15 | 0.11 | 0.52 | 0.84 | 1.11 | — | — |
| P/B Ratio | 0.62 | 0.66 | 0.84 | 0.56 | 1.31 | 2.15 | 2.67 | — | — |
| P/FCF | 3.86 | 4.12 | 18.82 | — | 45.93 | 40.77 | 50.29 | — | — |
| P/OCF | 2.30 | 2.45 | 5.26 | 3.08 | 9.02 | 13.56 | 20.42 | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.57 | 0.61 | 0.57 | 1.00 | 1.32 | 1.70 | — | — |
| EV / EBITDA | 10.49 | 10.64 | — | — | 14.43 | 17.54 | 22.68 | — | — |
| EV / EBIT | 27.62 | 23.02 | 239.52 | — | 28.30 | 27.50 | 47.17 | — | — |
| EV / FCF | — | 18.04 | 75.04 | — | 89.04 | 64.59 | 76.79 | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 38.7% | 38.7% | 38.0% | 37.6% | 40.2% | 41.8% | 42.8% | 43.0% | 43.4% |
| Operating Margin | 2.0% | 2.0% | 0.1% | -18.9% | 3.7% | 4.6% | 4.0% | 2.5% | -4.9% |
| Net Profit Margin | 0.2% | 0.2% | -1.7% | -20.5% | 1.5% | 2.8% | -0.5% | -2.2% | -9.4% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | 0.8% | 0.8% | -8.9% | -71.8% | 3.9% | 7.6% | -2.0% | -16.0% | -64.9% |
| ROA | 0.2% | 0.2% | -1.9% | -21.4% | 1.4% | 2.6% | -0.4% | -1.7% | -8.4% |
| ROIC | 2.4% | 2.4% | 0.1% | -18.8% | 3.3% | 4.0% | 2.9% | 1.9% | -4.4% |
| ROCE | 3.0% | 3.0% | 0.2% | -24.0% | 4.1% | 5.0% | 3.7% | 2.3% | -4.9% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 2.46 | 2.46 | 2.66 | 2.57 | 1.32 | 1.35 | 1.46 | 8.36 | 5.06 |
| Debt / EBITDA | 9.02 | 9.02 | — | — | 7.47 | 6.95 | 8.13 | 16.51 | — |
| Net Debt / Equity | — | 2.24 | 2.51 | 2.46 | 1.23 | 1.26 | 1.41 | 8.10 | 4.77 |
| Net Debt / EBITDA | 8.21 | 8.21 | — | — | 6.99 | 6.47 | 7.83 | 15.99 | — |
| Debt / FCF | — | 13.93 | 56.22 | — | 43.11 | 23.82 | 26.50 | — | 55.53 |
| Interest Coverage | 1.12 | 1.12 | 0.11 | -7.77 | 2.10 | 3.62 | 0.81 | 0.44 | -0.88 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.90 | 0.90 | 0.85 | 0.86 | 0.99 | 1.02 | 0.89 | 0.84 | 1.40 |
| Quick Ratio | 0.38 | 0.38 | 0.28 | 0.24 | 0.36 | 0.38 | 0.27 | 0.28 | 0.54 |
| Cash Ratio | 0.23 | 0.23 | 0.15 | 0.11 | 0.20 | 0.20 | 0.13 | 0.18 | 0.33 |
| Asset Turnover | — | 1.15 | 1.18 | 1.17 | 0.91 | 0.89 | 0.81 | 0.72 | 0.89 |
| Inventory Turnover | 6.20 | 6.20 | 5.80 | 5.70 | 5.53 | 5.01 | 5.22 | 5.28 | 5.29 |
| Days Sales Outstanding | — | 2.80 | 2.41 | 2.59 | 3.00 | 3.50 | 3.10 | 2.59 | 2.32 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 1.3% | 1.2% | — | — | 2.9% | 3.4% | — | — | — |
| FCF Yield | 25.9% | 24.3% | 5.3% | — | 2.2% | 2.5% | 2.0% | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $286M | $273M | $268M | $266M | $265M | $211M | $1.5B | $1.5B |
High fixed-cost operating leverage
Based on reported figures, Petco's P/S ratio of 0.13 suggests the market is pricing the company as a distressed retailer rather than a high-growth healthcare platform, with a forward P/E of 18.49 implying significant skepticism regarding the company's ability to achieve meaningful margin expansion in the near term.
The valuation gap between Petco and pure-play healthcare peers like IDEXX Laboratories highlights the market's refusal to assign a premium to the company's veterinary services segment. Investors appear to be discounting the stock based on the high probability that retail headwinds will continue to offset any potential gains from the service-led transformation strategy.
As reported in financial statements, Petco's ROIC has struggled to remain positive, hovering near zero or negative levels over the last ten quarters, which indicates that the company is failing to generate returns on invested capital that exceed its cost of capital in the current environment.
The persistent inability to drive ROIC above the cost of capital suggests that the capital-intensive expansion of in-store veterinary clinics has yet to reach the necessary scale to justify the investment. This trend warrants further investigation into whether the current store-in-store model is fundamentally capable of delivering the compounding returns required to create long-term shareholder value.
According to recent SEC filings, Petco's asset turnover has remained stagnant at approximately 0.29, revealing that the company's massive physical footprint is not generating sufficient revenue velocity to support its high fixed-cost structure compared to more agile, digital-first competitors in the specialty retail sector.
The cash conversion cycle, which remains consistently positive, indicates that the company is effectively financing its inventory through vendor payment terms, yet this does not translate into improved operational efficiency. The lack of improvement in asset turnover suggests that the physical store network may be underutilized, creating a drag on overall profitability.
Based on reported figures, Petco's debt-to-EBITDA ratio has frequently exceeded 30x in recent quarters, a level that appears unsustainable and suggests that the company's ability to service its debt is highly sensitive to even minor fluctuations in operating performance or interest rate environments.
The elevated leverage profile severely limits management's ability to pivot or invest in new growth initiatives, as a significant portion of cash flow is likely diverted toward interest obligations. Investors should monitor the interest coverage ratio closely, as the current levels indicate a precarious position that could necessitate further financing or asset divestitures.
The most commonly misapplied metric for Petco is the top-line revenue growth rate, which obscures the underlying margin erosion caused by the shift toward lower-margin consumables and the high fixed costs of the veterinary service infrastructure, as noted in recent financial disclosures.
Analysts should instead prioritize 'service-to-retail attachment rates' and 'clinic-level contribution margins' to assess the true health of the business model. Focusing on revenue growth alone ignores the reality that the company's current strategy may be trading high-quality earnings for low-margin volume, which is not a sustainable path to long-term profitability.
Includes 30+ ratios · 8 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying WOOF stock.
Petco Health and Wellness Company, Inc.'s current P/E ratio is 79.8x. The historical average is 49.6x. This places it at the 67th percentile of its historical range.
Petco Health and Wellness Company, Inc.'s current EV/EBITDA is 10.5x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 16.3x.
Petco Health and Wellness Company, Inc.'s return on equity (ROE) is 0.8%. The historical average is -18.9%.
Based on historical data, Petco Health and Wellness Company, Inc. is trading at a P/E of 79.8x. This is at the 67th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Petco Health and Wellness Company, Inc. has 38.7% gross margin and 2.0% operating margin.
Petco Health and Wellness Company, Inc.'s Debt/EBITDA ratio is 9.0x, indicating high leverage. A ratio above 4x may signal elevated financial risk.